Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
Back to Results

  • A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors

    Cancer Categories
    • Breast,Gastrointestinal (GI),Head and Neck,Lung
    Karmanos Trial ID
    • 2023-100
    NCT ID
    • NCT06241456
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase I
    Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
    • Phase I
    Principal Investigator

    Objective:

    Primary Objectives:

    • To evaluate the safety and tolerability of FT825 with or without cetuximab following CY/FLU or bendamustine
    • To define the RP2D of FT825 with or without cetuximab following CY/FLU or bendamustine

    Secondary Objectives:

    • To evaluate the antitumor activity of FT825 with or without cetuximab following CY/FLU or bendamustine
    • To characterize the PK of FT825 with or without cetuximab following CY/FLU or bendamustine
    Request an Appointment
    Refer a Patient
    NCI Dictionary of Cancer Terms
    KCI Clinical Trials App
    • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266